This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
KEB and skin cancer (2024)
Understanding the growth and spread of skin cancer in KEB will help to identify potential future treatments.
Prof Valerie Brunton works in Edinburgh, UK, on a rare type of epidermolysis bullosa (EB) called Kindler EB. This is caused by genetic changes that mean the Kindlin-1 protein doesn’t work properly. Patients suffering with this form of EB have thin skin that blisters and sunburns easily and an increased risk of skin cancer (squamous cell carcinoma). This work studies how the growth and spread of skin cancer is related to Kindlin-1 protein.
About our funding
| Research Leader | Prof Valerie Brunton |
| Institution | University of Edinburgh, UK |
| Types of EB | KEB |
| Patient involvement | None |
| Funding amount | £230,271.67 (co-funded with DEBRA Austria) |
| Project length | 3 years (extended due to Covid) |
| Start date | October 2020 |
| DEBRA internal ID | Brunton2 |
Project details
Outcome 1: Cancer cells with the KEB genetic change (lack of kindlin-1) have been shown to be more likely to form secondary cancers in other parts of the body.
Outcome 2: These cells have higher levels of a protein associated with cancer spread. Reducing this protein in the cells reduced their cancer-forming abilities and this could form the basis of a future treatment for squamous cell carcinoma in EB.
Outcome 3: Preliminary results showed that UV light increases proteins involved in inflammation in cancer cells. It increases the thickness of the skin (epidermis) with increasing growth in numbers of skin cells (keratinocytes) similar to the beginning of a cancer growing.
This work was published in the journal Oncogenesis in 2024. It was presented in talks to the Annual Meeting of the British Society for Investigative Dermatology in 2022 and the 99th Scottish Skin Biology Club Meeting in 2023. Also, in a poster presentation at the 1st Edinburgh Skin Network Symposium in 2023.
Research leader:
Professor Valerie Brunton is Chair of Cancer Therapeutics at the University of Edinburgh. Her interests are in understanding the biology of Kindler EB associated with skin atrophy (weakening), photosensitivity, and an increased risk of developing cutaneous squamous cell cancer. Her research aims to identify the key molecular pathways that underlie the pathology of Kindler EB to help identify ways in which to treat this.
Co-researchers:
Dr Adam Byron (biochemistry) University of Edinburgh and Prof Albena Dinkova-Kostova (cellular medicine) University of Dundee.
Collaborator:
Dr Alan Serrels (cancer / tumour microenvironment) University of Edinburgh.
“Our research has uncovered important changes in the tumour microenvironment (the normal cells and molecules that surround and support the growth of tumour cells), that are controlled by Kindlin-1. By studying these changes, we hope to gain a better understanding of how we can prevent the development and progression of skin cancer in patients with Kindler syndrome.”
– Prof Valerie Brunton
Grant Title: Understanding the role of Kindlin-1 loss in the development of squamous cell carcinoma
Kindler EB (KEB) is a rare skin disorder that develops early in life. People with KEB have skin blistering and develop thin or papery skin. They are also highly sensitive to ultraviolet (UV) radiation from the sun and sunburn easily. KEB also increases the risk of developing a type of skin cancer called squamous cell carcinoma. KEB occurs due to a genetic mutation in the FERMT1 gene. Mutations in FERMT1 results in the production of a defective protein called Kindlin-1.
Currently there is very little known about why the loss of a functional Kindlin-1 protein in the skin of people with KEB increases their risk of developing squamous cell carcinoma (SCC). The group have previously carried out experiments on skin cells grown in the laboratory which has shown that loss of Kindlin-1 sensitises cells to UV radiation. To understand why this happens they will use a model which mimics sun exposure to UV radiation. The next stage will look at whether loss of Kindlin-1 in the skin leads to increased skin cancer formation following UV exposure.
The 3 aims of this project are:
- Do changes in the tissue environment of tumours lacking Kindlin-1 contribute to their growth and metastatic spread?
- Do Kindlin-1 binding partners (molecules that interact), regulate cancer (SCC) growth?
- Does the loss of Kindlin-1 promote UV-induced skin cancer (SCC) formation?
DEBRA UK previously funded Professor Valerie Brunton at the University of Edinburgh towards research in Kindler Syndrome.
Kindler EB (KEB) is a rare skin disorder that develops early in life. People with KEB have skin blistering, and develop thin or papery skin. They are also highly sensitive to ultraviolet (UV) radiation from the sun and sunburn easily. KEB also increases the risk of developing a type of skin cancer called squamous cell carcinoma. KEB occurs due to a genetic mutation in the FERMT1 gene. Mutations in FERMT1 result in the production of a defective protein called Kindlin-1. Currently there is very little known about why the loss of a functional Kindlin-1 protein in the skin of people with KEB increases their risk of developing squamous cell carcinoma. We have previously carried out experiments on skin cells grown in the laboratory which have shown that loss of Kindlin-1 sensitises cells to UV radiation. To understand why this happens we will use a model which mimics sun-exposure to UV radiation. This will identify UV-induced changes that are specifically controlled by loss of Kindlin. The next stage will look at whether loss of Kindlin-1 in the skin leads to increased skin cancer formation following UV exposure (From 2022 & 2023 progress reports and final report 2024).